Stay updated with breaking news from Key Starting Materials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fractures in supply chain, compounded by stringent regulatory oversight, is causing ripples in generic drug manufacturers' production capacity in US, a report by IIFL Securities noted
US active drug shortages have further increased, after stabilizing at 300-310 drugs in CY23, to 323 drugs in 1QCY24 (as per ASHP data).
India’s pharmaceutical industry is at a pivotal juncture. With its well-established prowess in generic drug manufacturing, it has been called on by the world to build a reliable base for the manufacture of raw materials, which offers an opportunity for India to attract the bulk of the pharmaceutical supply chains away from China.
The anticipated bulk drug park in Jambusar is set to witness accelerated progress, with the Gujarat government gearing up to initiate the tender process for the park's communal facilities and the allotment of land to companies in the near ...
Spanning a sprawling 2,000 acres, this upcoming park is poised to play a pivotal role in expediting the domestic production of critical Key Starting Materials (KSMs), Active Pharmaceutical Ingredients (API), and pharmaceutical intermediates— commodities that are currently imported from China.